Regarding the Execution of a Global Exclusive License Agreement with Neurocrine Biosciences for Selective MC2R Antagonist SCO-483
NQ Score
82/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Scohia Pharma entered into a global exclusive license agreement with Neurocrine Switzerland GmbH for SCO-483, a novel MC2R antagonist. Scohia will receive a $20M upfront payment and up to $550M in milestones.